For Healthcare Professionals Outside the US
Tafinlar + Mekinist is indicated for adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection; for first-line treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation; for adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.

It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Home > Dosing > Oral dosing

Convenient oral dosing across all three indications

TAFINLAR 150 mg twice daily + MEKINIST 2 mg once daily1,2

Tafinlar® (dabrafenib) + Mekinist® (trametinib) dose frequency
Recommended starting dose: Tafinlar 150 mg twice daily + Mekinist 2 mg once daily.

12-hour interval between TAFINLAR doses
TAFINLAR + MEKINIST should be taken without food, ≥1 hour before or 2 hours after a meal
If a dose of TAFINLAR is missed, the does should only be taken if it is >6 hours until the next scheduled dose1
If a dose of MEKINIST is missed, the dose should only be taken if it is >12 hours until the next scheduled dose2

For your patients with melanoma, TAFINLAR + MEKINIST offers a more convenient option1,3-7

1_1
1_2

In the adjuvant melanoma setting, patients should be treated for a period of 12 months unless there is disease recurrence or unacceptable toxicity.1

border line

Talk to your patients about the benefits and convenience of oral administration.

border line
*Represents starting dose of most patients; recommended starting dose for patients with moderate or severe hepatic impairment is the same for encorafenib but 2 x 15 mg bid for binimetinib instead of 3 x 15 mg.

BID, twice daily.
References: 1. Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2020. 2. Mekinist Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2020. 3. Braftovi [prescribing information]. Boulder, CO: Array BioPharma Inc.; 2018. 4. Mektovi [prescribing information]. Boulder, CO: Array BioPharma Inc.; 2018. 5. Cotellic [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; 2018. 6. Zelboraf [prescribing information]. South San Francisco, CA: Genentech USA, Inc.; 2017. 7. Eek D, Krohe M, Mazar l, et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016;10:1609-1621.

COVID-19 Update


Novartis is closely monitoring the evolving COVID-19 pandemic. For the most recent information on how Novartis is responding, visit the COVID-19 Information Center.

During this time of uncertainty it is important to communicate with your patients about COVID-19 to clarify that they should not stop their treatments except under the direction of the treating physician, and to ensure that patients have sufficient drug to avoid any treatment interruptions.

Reach out to your Novartis representative with any questions related to Novartis products.

04/20  G-ONC-1230566

COMBI-AD was a double-blind, placebo-controlled, Phase 3 trial that compared Tafinlar + Mekinist vs placebo4

ELIGIBILITY REQUIREMENTS

  • Resection of histologically confirmed Stage IIIA, B, or C with BRAF V600E or BRAF V600K mutation
  • ECOG performance status ≤1
  • No prior systemic anticancer treatment or radiotherapy for melanoma
TAFINLAR 150 mg BID + MEKINIST
2 mg QD (n=438)
imgh22

Placebo (n=432)

STUDY ENDPOINTS

  • Primary endpoint was RFS
  • Secondary endpoints were OS, distant metastasis-free survival, freedom from relapse, and safety
COMBI-d phase 3 study: Tafinlar® (dabrafenib) + Mekinist® (trametinib) vs Tafinlar® monotherapy